Comparative efficacies of four amphotericin B formulations - Fungizone, amphotec (Amphocil), AmBisome, and Abelcet - against systemic murine aspergillosis
被引:61
作者:
Clemons, KV
论文数: 0引用数: 0
h-index: 0
机构:Santa Clara Valley Med Ctr, Dept Med, Div Infect Dis, San Jose, CA 95128 USA
Clemons, KV
Stevens, DA
论文数: 0引用数: 0
h-index: 0
机构:Santa Clara Valley Med Ctr, Dept Med, Div Infect Dis, San Jose, CA 95128 USA
Stevens, DA
机构:
[1] Santa Clara Valley Med Ctr, Dept Med, Div Infect Dis, San Jose, CA 95128 USA
[2] Calif Inst Med Res, San Jose, CA 95128 USA
[3] Stanford Univ, Dept Med, Div Infect Dis & Geog Med, Stanford, CA 94305 USA
We compared various amphotericin B formulations (no treatment or 0.8 mg of Fungizone [conventional deoxycholate amphotericin B] per kg of body weight, or 0.8, 4, or 8 mg of Amphocil, AmBisome, or Abelcet per kg of body weight) for treatment of systemic murine aspergillosis. In two studies, all formulations prolonged survival, with the results for AmBisome nearly equivalent to those for Fungizone; Amphocil and Abelcet were less effective or equivalent depending on the severity of infection. No survivors were cured in both kidneys and brain, but each formulation showed efficacy, especially in the kidneys. Although higher doses could be given, no lipid-based formulation showed consistent superiority over Fungizone or over each other.